AGMB-129 for Crohn's Disease

Recruiting at54 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Recruiting

Sponsor: Agomab Spain S.L.

Must not be taking: Cyclosporine, Tacrolimus, Sirolimus, others

Disqualifiers: Ulcerative colitis, Short bowel syndrome, others

No Placebo Group

Prior Safety Data

Approved in 3 Jurisdictions

Trial Summary

What is the purpose of this trial?

This trial is testing a new medication called AGMB-129 to help people with Crohn's disease who have painful narrowings in their intestines. The goal is to see if this medication can safely widen these narrowings and reduce symptoms like pain and vomiting, potentially avoiding the need for surgery.

Do I need to stop my current medications for the trial?

The trial requires that you maintain your current Crohn's disease medications throughout the study. However, you cannot be on certain medications like cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil within 8 weeks of screening, or Janus kinase inhibitors within 4 weeks of screening.

What makes the drug AGMB-129 unique for treating Crohn's disease?

The drug AGMB-129 is unique for Crohn's disease as it may involve targeting specific immune responses, such as neutralizing antibodies that recognize post-translational modifications, which could predict complicated forms of the disease. ^{1 2 3 4 5}

Research Team

Philippe Wiesel, MD

Principal Investigator

Agomab Therapeutics

Eligibility Criteria

This trial is for people with Crohn's Disease who have a narrowed intestinal section and up to two non-critical strictures in the ileum, confirmed by imaging. They should be experiencing manageable symptoms without needing hospitalization or surgery during the study and must maintain their current Crohn's medication.

Inclusion Criteria

I am on a stable treatment plan for Crohn's disease and agree to keep it the same during the study.

My symptoms are manageable and I'm not expected to need hospital care or surgery during the study.

I was diagnosed with Crohn's disease in my ileum or ileocolon at least 3 months ago.

Exclusion Criteria

I need to keep taking certain medications that affect my whole body.

I have or had a blood vessel or heart valve disorder.

I am currently taking specific medications.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

5 weeks

1 visit (in-person)

Treatment

Participants receive AGMB-129 or placebo for 12 weeks in a double-blind, placebo-controlled setting

12 weeks

4 visits (in-person) at Weeks 2, 4, 8, and 12

Follow-up

Participants are monitored for safety and effectiveness after treatment

2 weeks

1 visit (in-person)

Open-label extension

Participants may opt into continuation of treatment with AGMB-129 for up to 48 weeks

48 weeks

Regular visits throughout the extension period

Follow-up after extension

Participants are monitored for safety after the open-label extension

2 weeks

1 visit (in-person)

Treatment Details

Interventions

• AGMB-129 (Other)
• Placebo (Drug)

Trial Overview AGMB-129 is being tested against a placebo to see if it's safe for patients with fibrostenotic Crohn's Disease, how the body processes it (pharmacokinetics), and what effects it has on the body (pharmacodynamics). Participants will receive either a high or low dose of AGMB-129 or a placebo over 12 weeks.

Participant Groups

Group I: Placebo Experimental Treatment 1 Intervention

Matching placebo

Group II: AGMB-129 Low Experimental Treatment 1 Intervention

AGMB-129 low dose

Group III: AGMB-129 High Experimental Treatment 1 Intervention

AGMB-129 high dose

AGMB-129 is already approved in Canada for the following indications:

Approved in Canada as AGMB-129 for:

• Fibrostenosing Crohn's Disease (under investigation)

Who Is Running the Clinical Trial?

Agomab Spain S.L.

Lead Sponsor

Trials

4

Recruited

210+

Findings from Research

In a study of 273 patients with inflammatory bowel disease, pancreatic juice antibodies (PAB) were found in 31% of patients with Crohn's disease, making it a potential specific serological marker for this condition.

The presence of PAB did not correlate with disease activity or treatment response, indicating that while PAB may be specific to Crohn's disease, their role in disease pathogenesis remains uncertain.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Antibodies to a trypsin sensitive pancreatic antigen in chronic inflammatory bowel disease: specific markers for a subgroup of patients with Crohn's disease. Seibold, F., Weber, P., Jenss, H., et al.[2019]

In a study of 231 Israeli patients with Crohn's disease, the 3'-UTR SNP of the NFKBIA gene did not show a significant association with disease characteristics or susceptibility compared to 100 healthy controls.

The research highlights the complexity of genetic factors in Crohn's disease, indicating that population diversity may influence the role of susceptibility genes, but NFKBIA alone does not appear to affect disease onset or behavior in this cohort.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Lack of association of the 3'-UTR polymorphism in the NFKBIA gene with Crohn's disease in an Israeli cohort. Leshinsky-Silver, E., Karban, A., Cohen, S., et al.[2020]

In a study involving 260 participants (130 Crohn's disease patients and 130 healthy controls), no Mycobacterium avium subspecies paratuberculosis (MAP) was found in the blood of either group, suggesting that MAP may not be a direct cause of Crohn's disease.

Crohn's disease patients had a higher frequency of polymorphisms in the NOD2/CARD15 gene compared to healthy controls, indicating a potential genetic predisposition to the disease, but no link was found between these genetic variations and the presence of MAP in the blood.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Absence of mycobacterium avium subsp. paratuberculosis in Crohn's patients. Parrish, NM., Radcliff, RP., Brey, BJ., et al.[2018]

The study found that the NFKBIA 2758G/A and ICAM-1 K469E gene variants are not significant risk factors for Crohn's disease in a New Zealand population, based on an analysis of 182 patients and 188 controls.

However, the ICAM-1 K469E variant was associated with influencing the age of diagnosis for Crohn's disease, suggesting it may have a role in the disease's progression rather than its susceptibility.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Polymorphisms in NFKBIA and ICAM-1 genes in New Zealand Caucasian Crohn's disease patients. Hong, J., Leung, E., Fraser, AG., et al.[2022]

Anti-granulocyte macrophage-colony stimulating factor autoantibodies (aGMAbs) can be detected in patients with Crohn's disease years before diagnosis, indicating their potential as predictive biomarkers for complicated cases of the disease.

These aGMAbs specifically target altered glycosylation patterns on GM-CSF, which disrupts immune balance and promotes certain immune cell types, suggesting a mechanism by which they contribute to the pathogenesis of Crohn's disease.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Neutralizing Anti-Granulocyte Macrophage-Colony Stimulating Factor Autoantibodies Recognize Post-Translational Glycosylations on Granulocyte Macrophage-Colony Stimulating Factor Years Before Diagnosis and Predict Complicated Crohn's Disease. Mortha, A., Remark, R., Del Valle, DM., et al.[2023]

References

1. England pubmed.ncbi.nlm.nih.gov

Antibodies to a trypsin sensitive pancreatic antigen in chronic inflammatory bowel disease: specific markers for a subgroup of patients with Crohn's disease. [2019]

2. Germany pubmed.ncbi.nlm.nih.gov

Lack of association of the 3'-UTR polymorphism in the NFKBIA gene with Crohn's disease in an Israeli cohort. [2020]

3. England pubmed.ncbi.nlm.nih.gov

Absence of mycobacterium avium subsp. paratuberculosis in Crohn's patients. [2018]

4. Australia pubmed.ncbi.nlm.nih.gov

Polymorphisms in NFKBIA and ICAM-1 genes in New Zealand Caucasian Crohn's disease patients. [2022]

5. United States pubmed.ncbi.nlm.nih.gov

Neutralizing Anti-Granulocyte Macrophage-Colony Stimulating Factor Autoantibodies Recognize Post-Translational Glycosylations on Granulocyte Macrophage-Colony Stimulating Factor Years Before Diagnosis and Predict Complicated Crohn's Disease. [2023]